WILLOW ANNOUNCES A SECOND PROGRAM WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP AN ENZYME FOR MANUFACTURING A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT

Rapid success of first program leads to second collaboration to develop optimized enzyme for large scale manufacturing process Enzyme development expected to enable commercial-scale production of the API in 2025 SUNNYVALE, Calif., Sept. 18, 2024 /PRNewswire/ – Willow Biosciences Inc….

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.